Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 31, 2026 | September 02, 2026 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | Director | June 22, 2018 | June 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,466 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 9,480 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 9,466 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
OncoMed Pharmaceuticals Inc
Report date June 22, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2028-06-22 | Direct | 15,000 |
Reported balance
After 2018-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-22 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 1,382,272 · Balance 228,750 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 151,875 · Balance 76,875 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Row 3 · 2026-09-23 · Disposition to issuer · Disposed 76,875 · Balance 0 F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award. |
| Ordinary SharesSEC Table I · non-derivative | IndirectAs Custodian | 0 |
Reported balance
After 2026-09-23 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-23 · Disposition to issuer · Disposed 23,400 · Balance 0 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-09-23 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-23 · Disposition to issuer · Disposed 92,567 · Balance 0 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.24 · Expires 2032-02-24 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-23 · Disposition to issuer · Disposed 515,000 · Balance 0 F4: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.
F4: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2018 Filed May 16, 2018 23:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006940 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 987,237 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 105,000 shares were achieved and such shares will vest on May 20, 2018. F2 · balance_after: Includes 865 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:42 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 13,005 | $29.09 | $378,315.45 |
DisclosureSEC source: 0001179110-18-002614 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,372 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:23 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002131 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,377 Read SEC document |
| August 11, 2017 Filed Aug 11, 2017 22:26 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | PurchaseOrdinary Shares | 10,000 | $24.50 | $245,000.00 |
DisclosureSEC source: 0001179110-17-011428 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,377 Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3 | $144.22 | $432.65 |
DisclosureSEC source: 0001232524-17-000154 · edgardoc.xml · nonDerivative · entry 3 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,094 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 659 | $142.36 | $93,815.24 |
DisclosureSEC source: 0001232524-17-000154 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,097 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,415 | $0.00 Strike: $143.66 | $0.00 |
DisclosureSEC source: 0001232524-17-000154 · edgardoc.xml · derivative · entry 4 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,415 Underlying: Ordinary Shares · 3,415 shares Expires 2027-08-09 F3 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000154 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,756 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:58 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001140361-17-023616 · doc1.xml · derivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 5,000 | $150.00 | $750,000.00 |
DisclosureSEC source: 0001232524-17-000119 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,391 Read SEC document |
| May 20, 2017 Filed May 24, 2017 00:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,460 | $36.83 | $569,391.80 |
DisclosureSEC source: 0001179110-17-007882 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,377 F1 · balance_after: Includes 1,702 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2017. Read SEC document |
| February 20, 2017 Filed Feb 23, 2017 00:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 33,264 | $33.78 | $1,123,657.92 |
DisclosureSEC source: 0001179110-17-002995 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,135 Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002003 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903,399 Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 23:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,360 | $31.96 | $267,185.60 |
DisclosureSEC source: 0001179110-16-031982 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,399 F1 · balance_after: Includes 1,703 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.